| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Sulfobetaine-12 does not have a defined biological target as it is a zwitterionic surfactant rather than a pharmacologically active compound. Its function is physicochemical—it solubilizes proteins and membranes by disrupting hydrophobic interactions without denaturing proteins. The zwitterionic head group provides mild, non-denaturing solubilization properties. In biological systems, surfactants can disrupt cell membranes, but this is a non-specific effect. The compound is not designed for therapeutic use and has no specific receptor or enzyme targets.
|
|---|---|
| ln Vitro |
In vitro, sulfobetaine-12 exhibits no pharmacological activity as it is a surfactant. Its utility is demonstrated in protein solubilization and membrane protein studies, where it solubilizes proteins while maintaining their native structure and activity. The compound is commonly used in protein purification, membrane protein crystallization, and biochemical assays. In cell-based assays, surfactants can cause concentration-dependent cytotoxicity due to membrane disruption. However, sulfobetaine-12 is not used as a therapeutic agent. Its role is strictly chemical—providing mild, non-denaturing solubilization properties.
|
| ln Vivo |
Sulfobetaine-12 is not a pharmacologically active agent and does not exhibit in vivo therapeutic activity. It is used as a surfactant and protein solubilizing agent in biochemical research. The compound is not intended for human or animal exposure. It is used exclusively in laboratory settings for protein and membrane studies. No therapeutic efficacy has been reported for this compound. The compound is not administered to animals in pharmacological studies.
|
| Enzyme Assay |
In vitro assays for sulfobetaine-12 focus on its surfactant and protein solubilization properties rather than receptor binding. A standard protocol involves dissolving the compound in aqueous buffer at concentrations above its critical micelle concentration (CMC, typically 2-4 mM) and using it to solubilize membrane proteins or to prevent protein aggregation. Protein solubilization is assessed by SDS-PAGE or activity assays. For quality control, the compound is characterized by HPLC and purity analysis. Surface tension measurements and CMC determination are used for quality control.
|
| Cell Assay |
In vitro cell culture experiments with sulfobetaine-12 are typically cytotoxicity studies to assess the safety of the surfactant. A standard protocol involves culturing mammalian cells (e.g., HEK-293 or HeLa cells) in 96-well plates until 70-80% confluence. The compound is serially diluted in culture medium (typically 0-1000 µg/mL) and added to cells for 24-48 hours. Cell viability is assessed using MTT or resazurin reduction assays. Membrane integrity can be evaluated using LDH release assays. The compound is also used in studies of membrane protein solubilization from cell membranes.
|
| Animal Protocol |
In vivo animal studies with sulfobetaine-12 are limited to toxicological evaluations for safety assessment. Standard protocols for oral or dermal toxicity testing in rodents follow OECD guidelines. The compound is administered by gavage or applied to skin, and animals are monitored for clinical signs, body weight changes, and mortality. Histopathological examination of major organs is performed at study termination. The compound is not used in efficacy studies as it is not a therapeutic agent.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of sulfobetaine-12 are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 335.55, zwitterionic, surfactant), the compound would be expected to have very low oral bioavailability due to poor membrane permeability. If absorbed, it would likely distribute to lipid-rich tissues and be slowly eliminated. The compound may undergo metabolism via oxidation or degradation. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
It is safe at the current usage and concentration. Ingredient, concentration, and usage information can be found at: https://cir-reports.cir-safety.org Sulfobetaine-12 may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from moisture and strong oxidizing agents. No acute toxicity data are available. The compound is not intended for drug, household, or other uses. |
| Additional Infomation |
Lauryl sulfobetaine is an ammonium betaine in which the ammonium nitrogen atom is replaced by a dodecyl group, a 3-sulfopropyl group, and two methyl groups. It is used as a detergent. It is the conjugate base of N-dodecyl-N,N-dimethyl-3-ammonium-1-propanesulfonic acid.
See also: cocoyl dimethyl (3-sulfopropyl)betaine (note moved to). Sulfobetaine-12 is a zwitterionic surfactant used as a protein solubilizing agent and in membrane protein studies. It is also known as dodecyldimethyl(3-sulfopropyl)ammonium hydroxide inner salt and SB3-12. The compound has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is physicochemical—solubilizing proteins and membranes through mild, non-denaturing surfactant properties. |
| Molecular Formula |
C17H37NO3S
|
|---|---|
| Molecular Weight |
335.55
|
| Exact Mass |
335.249
|
| CAS # |
14933-08-5
|
| PubChem CID |
84703
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
250-260 °C (dec.)
|
| Flash Point |
110 °C
|
| LogP |
-1.91
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
22
|
| Complexity |
334
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])C([H])([H])C([H])([H])[N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(=O)(=O)[O-]
|
| InChi Key |
IZWSFJTYBVKZNK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H37NO3S/c1-4-5-6-7-8-9-10-11-12-13-15-18(2,3)16-14-17-22(19,20)21/h4-17H2,1-3H3
|
| Chemical Name |
3-[dodecyl(dimethyl)azaniumyl]propane-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (149.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9802 mL | 14.9009 mL | 29.8018 mL | |
| 5 mM | 0.5960 mL | 2.9802 mL | 5.9604 mL | |
| 10 mM | 0.2980 mL | 1.4901 mL | 2.9802 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
